RMG-05

RMG-05 is a therapeutic candidate currently in the preclinical and IND-enabling stages of development by RxOmeg Therapeutics (also known as Romeg Therapeutics). It is primarily being investigated for the treatment of Sjögren's disease and other rheumatological conditions. A notable aspect of the RMG-05 program is the concurrent development of a companion diagnostic intended to identify patient populations most likely to benefit from the therapy. While specific details regarding its molecular target and modality have not been publicly disclosed, RxOmeg typically focuses on the 505(b)(2) regulatory pathway, which often involves novel formulations or repurposed applications of established pharmaceutical agents.